AKT1 and leukemia: These early leads had suboptimal to satisfactory physiochemical properties although all showed improved biological activity on leukemia cells when compared to the tool RAC inhibitor NSC23766 [19] which showed cellular activities in the ~40–80 μM range ([20] and Fig. 2A).